Solomon Woldu, M.D.

  • Urology
  • Urologic Cancer, Masses, and Tumors
  • Bladder Cancer

Appointment New Patient Appointment Accepting Virtual Visits or 214-645-8765

Appointment New Patient Appointment or 214-645-8765

See Dr. Woldu's Locations

Biography

Solomon Woldu, M.D., is an Assistant Professor in the Department of Urology at UT Southwestern Medical Center. He specializes in urologic malignancies including bladder, kidney, prostate, and testicular cancers.

Dr. Woldu grew up in the Dallas-Fort Worth area and holds a bachelor's degree in biology from Washington University in St. Louis. He earned his medical degree at Columbia University College of Physicians and Surgeons, and stayed in New York City for his general surgery internship and urology residency at Columbia University Medical Center.

After his residency, he came back to Dallas to pursue a fellowship in oncology at UT Southwestern. The two-year Society of Urologic Oncology fellowship included both research and advanced clinical training in complex open and minimally invasive surgery. During this fellowship, he was the recipient of a National Institutes of Health training grant. His research interests are broad, and he has published over 100 peer-reviewed articles and multiple book chapters in urology. He regularly presents his research findings at national medical conferences.

Dr. Woldu sees patients at the UT Southwestern Main Campus in Dallas (West Campus Building 3, 4th Floor).

Meet Dr. Woldu

Urologist in Dallas and Fort Worth

After leaving Dallas – Fort Worth for college in St. Louis and then medical education and training in New York, Dr. Woldu found himself longing to come back home to Texas. He was fortunate to have made it back for a two-year fellowship specializing in the treatment of complex cancers involving the urologic organs, and feels even more fortunate to join the esteemed faculty at UT Southwestern.

“Cancers involving the urologic tract are among the most commonly diagnosed malignancies,” says Dr. Woldu. “These diseases are not only life-threatening, but treatments are often associated with significant lifestyle changes that can affect intimacy and well-being. I’m particularly cognizant of these aspects, and insist that the patient’s overall well-being and goals are at the forefront of any decision making.”

“Each patient and each cancer is unique, and I employ a personalized approach to each treatment decision,” says Dr. Woldu.

“Guidelines are just guidelines. A ‘cookie cutter’ approach might have worked in the past, but technology has advanced significantly in the last few years. Multi-modal approaches to treating cancer now include genetic analysis of tumors, traditional chemotherapy, radiation, immunotherapy, and surgery. When surgery is required, I offer patients robotic or minimally invasive options whenever possible so they can get back to their lives as soon as possible.”

See More

Education & Training
  • Residency - Columbia Presbyterian Medical Center (2011-2016), Urology
  • Medical School - Columbia University College of Physicians and Surgeons (2006-2010)
  • Internship - Columbia Presbyterian Medical Center (2010-2011), General Surgery
  • Fellowship - UT Southwestern Medical Center (2016-2018), Urologic Oncology
Professional Associations & Affiliations
  • American Board of Urology
  • Society of Urologic Oncology
Honors & Awards
  • D Magazine Best Doctor 2022
Research
  • Singla N, Hutchinson RC, Ghandour RA, Friefeld Y, Fang D, Sagalowsky AI, Lotan Y, Bagrodia A, Margulis V, Hammers HJ, Woldu SL. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: A national population-based analysis. Urol Oncol. Accepted for Publication 2020.
  • Yeh HC, Margulis V, Singla N, Hernandez E, Panwar V, Woldu SL, Karam JA, Wood CG, Weizer AZ, Raman D, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Li CC, Ke HL, Li WM, Lee HY, Rappaort LM, Lotan Y, Kapur P, Shariat SF, Hsieh JT, Wu WJ. PTRF Independently Predicts Progression and Survival in Multiracial Upper Tract Urothelial Carcinoma Following Radical Nephroureterectomy. Urol Oncol. 2019 Dec 17:S1078-1439(19)30483-1. doi: 10.1016/j.urolonc.2019.11.010. PMID: 31862213.
  • Lafin JT, Singla N, Woldu SL, Lotan Y, Lewis CM, Majmudar K, Savelyeva A, Kapur P, Margulis V, Strand DW, Murray MJ, Amatruda JF, Bagrodia A. Serum MicroRNA-371a-3p Levels Predict Viable Germ Cell Tumor in Chemotherapy-naïve Patients Undergoing Retroperitoneal Lymph Node Dissection. Eur Urol. 2020 Feb;77(2):290-292. doi: 10.1016/j.eururo.2019.10.005. Epub 2019 Nov 5.PMID: 31699528.
  • Singla N, Elias R, Ghandour RA, Freifeld Y, Bowman IA, Rappaort L, Enikeev M, Lohrey J, Woldu SL, Gahan JC, Bagrodia A, Brugarolas J, Hammers HJ, Margulis V. Pathologic Response and Surgical Outcomes in Patients Undergoing Nephrectomy Following Receipt of Immune Checkpoint Inhibitors for Renal Cell Carcinoma. Urol Oncol. 2019 Sep 12. pii: S1078-1439(19)30330-8. doi: 10.1016/j.urolonc.2019.08.012. PMID: 31522865
  • Freifeld Y, Woldu SL, Singla N, Clinton T, Bagrodia A, Hutchinson R, Lotan Y, Margulis V. Impact of Hospital Case Volume on Outcomes Following Radical Nephrectomy and Inferior Vena Cava Thrombectomy. Eur Urol Oncol. 2018 Nov 16. pii: S2588-9311(18)30186-X. doi: 10.1016/j.euo.2018.10.005. PMID: 31411983
  • Freifeld Y, Ghandour R, Singla N, Woldu SL, Clinton T, Kulangara R, Bagrodia A, Matin SF, Petros FG, Raman JD, Robyak H, Yan J, Zhu H, Rapoport L, Lotan Y, Margulis V. Preoperative Predictive Model and Nomogram for Disease Recurrence Following Radical Nephroureterectomy for High Grade Upper Tract Urothelial Carcinoma. Urol Oncol. 2019 Aug 1. pii: S1078-1439(19)30238-8. doi: 10.1016/j.urolonc.2019.06.009. PMID: 31378586.
  • Ghandour R, Ashbrook C, Friefeld Y, Singla N, El-Asmar M, Lotan Y, Margulis V, Eggener S, Woldu SL, Bagrodia A. Nationwide Patterns of Care for Stage II Nonseminomatous Germ Cell Tumor of the Testicle. Cancer. 2019 Jul 29. doi: 10.1002/cncr.32427. PMID: 31355922.
  • Woldu SL, Moore JA, Ci B, Freifeld Y, Clinton TN, Aydin AM, Singla N, Krabbe LM, Hutchinson RC, Amatruda JK, Sagalowsky A, Lotan Y, Arriaga Y, Margulis V, Xie Y, Bagrodia A. Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes. Eur Urol Oncol. 2018. Aug;1(3):242-251. doi: 10.1016/j.euo.2018.04.005. PMID:3105826.
  • Lafin T, Bagrodia A, Woldu SL, Amatruda JF. New Insigns into Germ Cell Tumor Genomics. Andrology. 2019. Jul;7(4):507-515. doi: 10.1111/andr.12616. PMID:30896089.
  • Singla N, Walker JT, Woldu SL, De La Fuente K, Araj E, Swartz B, Kapur P, Roehrborn CG. Does proximity of positive prostate biopsy core to capsular margin help predict side-specific extracapsular extension at prostatectomy? Can J Urol. 2019 Feb;26(1):9634-9643. PMID: 30797246.
  • Aydin AM, Singla N, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Westerman ME, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V, Krabbe LM. Prognostic Significance of BAP1 Expression in High-Grade Upper Tract Urothelial Carcinoma: a Multi-Institutional Study. World J Urol. 2019 Feb 13. doi: 10.1007/s00345-019-02678-x. PMID: 30759271.
  • Matulay JT, Woldu SL, Lim A, Narayan VM, Li G, Kamat AM, Anderson CB. The Impact of Squamous Histology on Survival in Patients with Muscle-Invasive Bladder Cancer. Urol Oncol. 2019 Jan 28. pii: S1078-1439(19)30021-3. doi: 10.1016/j.urolonc.2019.01.020. PMID: 30704959.
  • Bhanvadia RR, Woldu SL, Margulis V, Subramaniam RM, Bagrodia A. Incidental Detection of Metastatic Penile Squamous-Cell Carcinoma With Anti-1-Amino-3-F-18-Fluorocyclobutane-1-Carboxylic Acid (18F-Fluciclovine) PET/CT in a Patient With Recurrent Prostate Cancer. Clin Genitourin Cancer. 2019 Feb;17(1):e184-e186. doi: 10.1016/j.clgc.2018.10.014. PMID: 30454969.
  • Friefeld Y, Xi Y, Passoni N, Woldu SL, Hornberger B, Goldberg K, Bagrodia A, Raj G, Margulis V, Cadeddu JA, Lotan Y, Francis F, Pedrosa I, Roehrborn CG, Costa DN. Optimal Sampling Scheme in Men with Abnormal Multiparametric MRI undergoing MRI-TRUS Fusion. Urologic Oncology. 2019 Jan;37(1):57-62. doi: 10.1016/j.urolonc.2018.10.009. PMID: 30446460.
  • Woldu SL, Sanli O, Clinton TN, Lotan Y. Validating the Predictors of Outcomes After Radical Cystectomy for Bladder Cancer. Cancer. 2019 Jan 15;125(2):223-231. doi: 10.1002/cncr.31799. PMID: 30291813.
  • Woldu SL, Matulay JT, Clinton TN, Singla N, Friefeld Y, Sanli O, Krabbe LM, Hutchinson RC, Lotan Y, Hammers H, Hannan R, Brugarolas J, Bagrodia A, Margulis V. Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study. Clin Genitourin Cancer. 2018 Aug 25. pii: S1558-7673(18)30444-0. doi: 10.1016/j.clgc.2018.08.001. PMID: 30217763.
  • Woldu SL, Bagrodia A. Update on Epidemiologic Considerations and Treatments. Curr Opin Urol. 2018 Sep;28(5):440-447. doi: 10.1097/MOU.0000000000000532. PMID: 30004908.
  • Freifeld Y, Krabbe LM, Clinton TN, Woldu SL, Margulis V. Therapeutic Strategies for Upper Tract Urothelial Carcinoma. Expert Rev Anticancer Ther. 2018 Aug;18(8):765-774. doi: 10.1080/14737140.2018.1481395. Epub 2018 Jun 8. PMID: 29848133.
  • Singla N, Krabbe LM, Aydin AM, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V. Multi-institutional Evaluation of the Prognostic Significance of EZH2 Expression in High-Grade Upper Tract Urothelial Carcinoma. Urologic Oncology. 2018 May 7. pii: S1078-1439(18)30126-1. PMID: 29748098.
  • Lotan Y, Woldu SL, Sanli O, Black PC, Millowsky MI. Modeling Cost-Effectiveness of a Biomarker-Based Approach to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. British Journal of Urology International. 2018 Mar 31. doi: 10.1111/bju.14220. PMID: 29603871.
  • Woldu SL, Kapur P, Brugarolas J, Margulis V. What is the Role of Nephrectomy Following Complete Response to Checkpoint Inhibitors? Urology Case Reports. Accepted. March 2018.
  • Woldu SL, Hutchinson RC, Singla N, Hornberger B, Roehrborn CG, Lotan Y. Prospective Monitoring and Adapting Strategies for Prevention of Infection Following Transrectal Prostate Procedures. Urology practice. 2018 Mar;5(2):124-131. PMID: 29687052
  • Hutchinson R, Rew C, Chen G, Woldu SL, Krabbe LM, Meissner M, Sheth K, Singla N, Shakir N, Master VA, Karam JA, Matin SF, Borregales LD, Wood C, Masterson T, Thompson RH, Boorjian SA, Leibovich BC, Abel EJ, Bagrodia A, Margulis V. The Adverse Survival Implications of Bland Thrombus in Renal Cell Carcinoma with Venous Tumor Thrombus. Urology. Urology. 2018 Feb 27. pii: S0090-4295(18)30176-6. doi: 10.1016/j.urology.2018.02.019. [Epub ahead of print]. PMID: 29499258
  • Margolin EJ, Matulay JT, Li G, Meng X, Chao B, Vijay V, Silver H, Clinton TN, Krabbe LM, Woldu SL, Singla N, Bagrodia A, Margulis V, Huang HC, Bjurlin MA, Shah O, Anderson CB. Discordance Between Ureteroscopic Biopsy and Final Pathology. J Urol. 2018 Feb 7. pii: S0022-5347(18)30191-5. doi: 10.1016/j.juro.2018.02.002. [Epub ahead of print] PMID: 29427584
  • Woldu SL, Ci B, Hutchinson RC, Krabbe LM, Singla N, Passoni NM, Clinton TN, Raj GV, Miller DS, Sagalowsky AI, Lotan Y, Xie Y, Margulis V, Bagrodia A. Usage and Survival Implications of Surgical Staging of Inguinal Lymph Nodes in Intermediate to High-Risk, Clinically Localized Penile Cancer: A Propensity-Score Matched Analysis. Urol Oncol. 2017 Dec 26. pii: S1078-1439(17)30611-7. doi: 10.1016/j.urolonc.2017.12.001. [Epub ahead of print] PMID: 29288008
  • Woldu SL, Hutchinson RC, Krabbe LM, Sanli O, Margulis V. The Rho GTPase Signalng Pathway in Urothelial Carcinoma. Nat Rev Urol. 2017 Nov 14. doi: 10.1038/nrurol.2017.184. PMID: 29133936.
  • Singla N, Fang D, Su X, Bao Z, Cao Z, Robyak H, Xiong G, Zhang L, Woldu SL, Hutchinson R, Sagalowsky A, Lotan Y, Li X, Zhou L, Raman JD, Margulis V. Preoperative predictors of nonorgan-confined disease in upper-tract urothelial carcinoma differ between China and the United States. Urol Oncol. 2017 Nov 23. pii: S1078-1439(17)30566-5. doi: 10.1016/j.urolonc.2017.10.029. PMID: 29174945.
  • Woldu SL, Matulay JT, Clinton TN, Singla N, Krabbe LM, Hutchinson RC, Sagalowsy AI, Lotan Y, Margulis V, Bagrodia A. Impact of Hospital Case Volume on Testicular Cancer Outcomes and Practice Patterns. Urologic oncology. Urol Oncol. 2017 Sep 18. pii: S1078-1439(17)30455-6. doi: 10.1016/j.urolonc.2017.08.024. PMID: 28935185.
  • Clinton TN, Bagrodia A, Lotan Y, Margulis V, Woldu SL. Tissue-Based Biomarkers in Prostate Cancer. Expert Review of Precision Medicine and Drug Development. 2017;2(5):249-260. doi: 10.1080/23808993.2017.1372687. PMID: 29226251.
  • Woldu SL, Aydin AM, Rao AV, Hutchinson RC, Singla N, Clinton TN, Krabbe LM, Passoni NM, Raj GV, Miller DS, Amatruda JF, Sagalowsky AI, Lotan Y, Arriaga Y, Margulis V, Bagrodia. Differences at Presentation and Treatment of Testicular in Hispanic Men: Institutional and National Hospital-Based Analysis. Urology. 2017 Oct 24. pii: S0090-4295(17)31102-0. doi: 10.1016/j.urology.2017.08.059. [Epub ahead of print]. PMID: 29079210.
  • Hutchinson R, Singla N, Krabbe LM, Woldu SL, Chen G, Rew C, Tachibana I, Lotan Y, Cadeddu JA, Margulis V. Increased Use of Antihypertensive Medications After Partial Nephrectomy vs. Radical Nephrectomy. Urologic oncology. 2017 Jul 15. pii: S1078-1439(17)30341-1. doi: 10.1016/j.urolonc.2017.06.057. PMID: 28720410.
  • LM Krabbe, Heitplatz B, Preuss S, Hutchinson RC, Woldu SL, Singla N, Boegeman M, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Rapoport L, Glybochko P, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Xylinas E, Margulis V. Prognostic Value of PD-1 and PD-L1 Expression in Patients with High-Grade Upper Tract Urothelial Carcinoma. J Urol. 2017 Dec;198(6):1253-1262. doi: 10.1016/j.juro.2017.06.086. Epub 2017 Jun 28. PMID: 28668287.
  • Yin Y, L Ri, Xu K, Ding S, Li J, Baek GH, Ramanand S, Ding S, Liu Z, Gao Y, Kanchwala M, Li X, Hutchinson R, Liu X, Woldu SL, Xing C, Neil Desai, Feng F, Burma S, de Bono J, Dehm S, Mani RS, Chen B, Raj GV. Androgen Receptor Variants Mediate DNA Repair Following Radiation in Prostate Cancer. Cancer research. 2017 Jul 28. pii: canres.0164.2017. doi: 10.1158/0008-5472.CAN-17-0164. PMID: 28754673.
  • Clinton TN, Woldu SL, Raj GV. Degarelix versus Luteinizing Hormone-Releasing Hormone Agonist for the Treatment of Prostate Cancer. Expert opinion on pharmacotherapy. 2017 Jun;18(8):825-832. PMID: 28480768.
  • Woldu SL, Sanli O, Lotan Y. Tackling Non-Muscle Invasive Bladder Cancer in the Clinic. Expert reviews in anticancer therapy. 2017 May;17(5):467-480. PMID: 28359179.
  • Woldu SL, Aydin AM, Hutchinson RC, Boegemann M, Bagrodia A, Lotan Y, Margulis V, Krabbe LM. Spotlight on Atezolizumab and its Potential in the Treatment of Advanced Urothelial Cancer. Oncotargets and therapy. 2017 Mar 9;10:1487-1502. doi: 10.2147/OTT.S109453. eCollection 2017 Mar 9. Review. PMID: 28331342.
  • Woldu SL, Bagrodia A, Lotan Y. Guideline of Guidelines – Non-Muscle Invasive Bladder Cancer. British journal of urology international. 2017 Jan 6. doi: 10.1111/bju.13760. PMID: 28058776.
  • Patil R, Woldu SL, Lucas E, Quinn A, Francis F, Margulis V. Metastatic Melanoma to the Bladder: Case Report and Review of Literature. Urology case reports. 2017 Jan 10;11:33-36. doi: 10.1016/j.eucr.2016.10.017. PMID: 28083484.
  • Singla N, Walker J, Woldu S, Passoni N, de la Fuente K, Roehrborn C. Formalin Disinfection of Prostate Biopsy Needles May Reduce Post-Biopsy Infectious Complications. Prostate cancer and prostatic diseases. 2017 Jan 24. doi: 10.1038/pcan.2016.70. PMID: 28117384.
  • Woldu SL, Raj GV. The Surgeon-Scientist – A Dying Breed? Nature reviews urology. 2016 Nov 22. doi: 10.1038/nrurol.2016.236. PMID: 27872479.
  • Woldu SL, Krabbe LM, Shariat SF, Lotan Y. Improving Diagnostic Molecular Tests to Monitor Urothelial Carcinoma Recurrence. Expert Review of Molecular Diagnostics. 2016 Nov;16(11):1189-1199. PMID: 27696932.
  • Woldu SL, Margulis V. Single Nucleotide Polymorphisms of the Vascular Endothelial Growth Factor Receptor – A Promising Biomarker. British journal of urology international. 2016 Dec;118(6):847-848. doi: 10.1111/bju.13617. PMID: 27870360
  • Woldu SL, Amatruda JF, Bagrodia A. Testicular Germ Cell Tumor Genomics. Current Opinions Urology. 2016 Aug 31. PMID: 27584029.
  • Biles MJ, DeCastro GJ, Woldu SL. Renal Function Following Nephron Sparing Procedures: Simple a Matter of Volume? Current urologic reports. 2016 Jan;17(1):8. 2016 Jan;17(1):8. PMID: 26754033.
  • Weinberg AC, Wright, JD, Whalen MJ, Paulucci DJ, Woldu SL, Weinberg AC, Woldu SL, Berger SA, Deibert CM, Korets R, Hershman DL, Neugut AL, Badani KK. Utilization of Partial Nephrectomy Following the Acquisition of a Surgical Robot: A Population-Based Study. Urology practice. July 2015.
  • Whalen M, Shapiro EY, Rothberg MB, Woldu SL, RoyChoudhury A, Patel T, Badani KK. Close Surgical Margins after Radical Prostatectomy Mimic Biochemical Recurrence Rates of Positive Margins. Urologic oncology. 2015; 33(11):494.e9-494.e14. PMID: 26259665.
  • Woldu SL, McKiernan JM. Reoperative Retroperitoneal Surgery: Etiology and Clinical Outcome. Urologic Clinics of North America (Book Chapter). The Urologic clinics of North America. 2015; 42(3):381-92. PMID: 26216825.
  • Weinberg AC, Woldu SL, Wen T, Deibert CM, Badani KK. Utilization and Perioperative Complications of Laparoscopic Cryoablation vs. Robotic Partial Nephrectomy for Localized Renal Tumors. International braz j urol : official journal of the Brazilian Society of Urology. 2015; 41(3):473-85.PMID: 26200540.
  • Meyer A, Woldu SL, Weinberg AC, Thoreson GR, Pierorazio P, Matulay JT, Benson MC, DeCastro GJ, McKiernan JM. Predicting Renal Parenchymal Loss Following Nephron Sparing Surgery. The Journal of urology. 2015; 194(3):658-63. PMID: 25818030.
  • Woldu SL, Matulay JT, Silva MV, Ahn JJ, Zviti RO, Lambert SM, Alam S, Casale P. Serum Cystatin C as Novel Marker to Differentiate Pseudo-Azotemia in Setting of Intra-Peritoneal Urine Extravasation. Urology. 2015; 85(4):918-20. PMID: 25669737.
  • Woldu SL, Thoreson GR, Okhunov Z, Ghandour R, Rothberg MB, RoyChoudhury A, Newhouse JH, Helmy MA, Badani KK, Landman J, Caddedu JA, McKiernan JM. Comparison of Renal Parenchymal Volume Preservation Between Partial Nephrectomy, Cryoablation, and Radiofrequency Ablation Using 3-D Volume Measurements. Journal of endourology / Endourological Society. 2015; 29(8):948-55. PMID: 25578645.
  • Korets R, Weinberg AC, Alberts BD, Woldu SL, Mann MJ, Badani KK. Utilization and Timing of Blood Transfusions Following Open and Robot Assisted Radical Prostatectomy. Journal of endourology / Endourological Society. 2014; 28(12):1418-23. PMID: 25099954.
  • Yamany T, Woldu SL, Korets R, Badani KK. Effect of Post-Call Fatigue on Surgical Skills Measured by a Robotic Simulator. Journal of endourology / Endourological Society. 2015; 29(4):479-84. PMID: 25285896.
  • Woldu SL, Weinberg AC, Korets R, Ghandour R, Danzig MR, RoyChoudhury A, Kalloo SD, Benson MC, DeCastro GJ, McKiernan JM. Who Really Benefits From Nephron Sparing Surgery? Urology. 2014; 84(4):860-7. PMID: 25260447.
  • Alberts B, Woldu SL, Weinberg AC, Danzig M, Badani KK. Venous Thromboembolism After Major Urologic Oncologic Surgery: A Focus on the Incidence and Timing of Thromboembolic Event after 27,455 Operations. Urology. 2014; 84(4):799-806. PMID: 25156513
  • Woldu SL, Weinberg AC, Shapiro E, RoyChoudhury A, Chase H, McKiernan JM, DeCastro GJ. Renal Insufficiency is Associated with an Increased Risk of Papillary Renal Cell Carcinoma Histology. International urology and nephrology. 2014; 46(11):2127-32. PMID: 25000896.
  • Weinberg AC, Woldu SL, Bergman A, RoyChoudhury A, Patel T, Wambi C, Badani KK. Dorsal Penile Block for Post-Robotic Assisted Radical Prostatectomy Catheter Pain: A Randomized, Double-Blinded, Placebo-Controlled Trial. SpringerPlus. 2014; 3:181. PMID: 24790826.
  • Woldu SL, Ordonez MA, Devine P, Wright J. Urologic Considerations of Placenta Accreta. Urologia internationalis. 2014; 93(1):74-9. PMID: 24732915.
  • Woldu SL, Weinberg AC, Bergman A, Shapiro EY, Motamedinia P, Korets R, Badani KK. Pain and Analgesic Usage After Robotic Assisted Radical Prostatectomy. Journal of endourology / Endourological Society. 2014; 28(5):544-8. PMID: 24400824.
  • Woldu SL, Patel T, Shapiro EY, Bergman AM, Badani KK. Outcomes with Delayed Dorsal Vein Complex Ligation During RALP. The Canadian journal of urology. 2013; 20(6):7079-83. PMID: 24331354.
  • Woldu SL, Nees SN, Deibert CM, Spencer BA, Poon SA, Glassberg KI. Physical Exam and Ultrasound Characteristics of Right Varicoceles in Adolescents with Left Varicoceles. Andrology. 2013; 1(6):936-42. PMID: 24124170.
  • Korets R, Woldu SL, Nees SN, Spencer BA, Glassberg KI. Testicular Symmetry and Adolescent Varicocele -- Does It Need Follow-up? The Journal of urology. 2011; 186(4 Suppl):1614-8. PMID: 21862060.
  • Woldu SL, Van Batavia JP, Poon SA, Raimondi PM, Glassberg KI. Is Adolescent Varicocelectomy Safe After Previous Inguinal Surgery? The Journal of urology. 2010; 184(4 Suppl):1716-21. PMID: 20728158.
  • Van Batavia JP, Woldu SL, Raimondi PM, Spencer BA, Insel BJ, Poon SA, Glassberg KI. Adolescent Varicocele: Influence of Tanner Stage at Presentation on the Presence, Development, Worsening and/or Improvement of Testicular Hypotrophy without Surgical Intervention. The Journal of urology. 2010; 184(4 Suppl):1727-32. PMID: 20728152.
  • Woldu SL, Barlow LJ, Patel T, Hruby GW, Benson MC, McKiernan JM. Single Institutional Experience with Nephron Sparing Surgery for Pathological Stage T3b Renal Cell Carcinoma Confined to the Renal Vein. Urology. 2010; 76(3):639-42. PMID: 20163841.
  • Ritch CR, Murphy AM, Woldu SL, Reiley E, Hensle TW. Overnight Urethral Stenting After Tubularized Incised Plate Urethroplasty (TIP) for Distal Hypospadias. Pediatric surgery international. 2010; 26(6):639-42. PMID: 20419376.
  • Yeh HC, Li CC, Chien TM, Li CY, Cheng YC, Woldu SL, Robyak H, Huang CN, Ke HL, Li WM, Lee HY, Yeh BW, Yang SF, Tu HP, Sagalowsky AI, Raman JD, Singla N, Margulis V, Lotan Y, Hsieh JT, Wu WJ. Interethnic differences in the impact of body mass index on upper tract urothelial carcinoma following radical nephroureterectomy. World J Urol. 2020 Apr 21. doi: 10.1007/s00345-020-03204-0.
  • Yeh HC, Li CC, Wen SC, Singla N, Woldu SL, Robyak H, Huang CN, Ke HL, Li WM, Lee HY, Li CY, Yeh BW, Yang SF, Tu HP, Shariat SF, Sagalowsky AI, Raman JD, Lotan Y, Hsieh JT, Margulis V, Wu WJ. Validation of Hyponatremia as a Prognostic Predictor in Multiregional Upper Tract Urothelial Carcinoma. J Clin Med. 2020 Apr 23;9(4). pii: E1218. doi: 10.3390/jcm9041218
  • Singla N, Christie A, Freifeld Y, Ghandour RA, Woldu SL, Clinton TN, Petros FG, Robyak H, Yeh HC, Fang D, Enikeev D, Bagrodia A, Sagalowsky AI, Lotan Y, Raman JD, Matin SF, Margulis V. Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma. Urol Oncol. 2020 May 16:S1078-1439(20)30180-0. doi: 10.1016/j.urolonc.2020.04.025. Online ahead of print.PMID: 32430254
  • Freifeld Y, Ghandour R, Singla N, Woldu S, Bagrodia A, Lotan Y, Rapoport LM, Gazimiev M, Delafuente K, Kulangara R, Robyak H, Petros FG, Raman JD, Matin SF, Margulis V. Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy. Urol Oncol. 2020 Jul 5:S1078-1439(20)30196-4. doi: 10.1016/j.urolonc.2020.05.002. Online ahead of print. PMID: 32641241
  • Lotan Y, Chaplin I, Ahmadi H, Meng X, Roberts S, Ladi-Seyedian S, Bagrodia A, Margulis V, Woldu S, Daneshmand, S. Prospective evaluation of blue-light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer.2 BJU Int. 2020 Jul 10. doi: 10.1111/bju.15166. Online ahead of print. PMID: 32648957
  • Ghandour RA, Kusin S, Wong D, Meng X, Singla N, Freifeld Y, Bagrodia A, Margulis V, Sagalowsky A, Lotan Y, Woldu SL. Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy? Urol Oncol 2020 Jul 16;S1078-1439(20)30263-5.doi: 10.1016/j.urolonc.2020.05.032. PMID: 32684514
  • Chertack N, Ghandour RA, Singla N, Freifeld Y, Hutchinson RC, Courtney K, Bowman IA, Arafat W, Meng X, Moore JA, Aydin AM, Sagalowsky AI, Margulis V, Lotan Y, Woldu SL, Bagrodia A. Overcoming sociodemographic factors in the care of patients with testicular cancer at a safety net hospital.2 Cancer. 2020 Aug 10. doi: 10.1002/cncr.33076. Online ahead of print. PMID: 32776520
  • Bhanvadia R, Ashbrook C, Bagrodia A, Lotan Y, Margulis V, Woldu S. Population-based analysis of cost and peri-operative outcomes between open and robotic primary retroperitoneal lymph node dissection for germ cell tumors.2 World J Urol. 2020 Aug 14. doi: 10.1007/s00345-020-03403-9. Online ahead of print. PMID: 32797261
  • Ghandour R, Miranda AF, Singla N, Meng X, Enikeev D, Woldu S, Bagrodia A, Cadeddu J, Gahan J, Margulis V. Feasibility and Safety of Robotic Excision of Ipsilateral Retroperitoneal Recurrence after Nephrectomy for Renal Cell Carcinoma.2 Urology. 2020 Aug 20:S0090-4295(20)31002-5. doi: 10.1016/j.urology.2020.07.060. Online ahead of print. PMID: 32828868
  • Badia RR, Abe D, Wong D, Singla N, Savelyeva A, Chertack N, Woldu SL, Lotan Y, Mauck R, Ouyang D, Meng X, Lewis CM, Majmudar K, Jia L, Kapur P, Xu L, Frazier AL, Margulis V, Strand DW, Coleman N, Murray MJ, Amatruda JF, Lafin JT, Bagrodia A. Real-World Application of Pre-orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management.2 J Urol. 2020 Aug 28:101097JU0000000000001337. doi: 10.1097/JU.0000000000001337. Online ahead of print. PMID: 32856980
  • Bhanvadia R, Ashbrook C, Gahan J, Mauck R, Bagrodia A, Margulis V, Lotan Y, Roehrborn C, Woldu S. Perioperative Outcomes and Cost of Robotic versus Open Simple Prostatectomy in the Modern Robotic Era: Results from the National Inpatient Sample. BJU Int. 2020 Sep 27. doi: 10.1111/bju.15258. Epub ahead of print. PMID: 32981194.
  • Cooley LF, Weiner AB, Meng X, Woldu SL, Meeks JJ, Lotan Y. Survival by T Stage for Patients with Localized Bladder Cancer: Implications for Future Screening Trials. Bladder Cancer. 2020 Oct 25. DOI 10.3233/BLC-200381
  • Kenigsberg AP, Smith W, Meng X, Ghandour R, Rapoport L, Bagrodia A, Lotan Y, Woldu SL, Margulis V. Robotic Nephroureterectomy vs Laparoscopic Nephroureterectomy: Increased Utilization, Rates of Lymphadenectomy, Decreased Morbidity Robotically. J Endourol. 2020 Nov 16. doi: 10.1089/end.2020.0496. Online ahead of print. PMID: 33081512
  • Fang D, Singla N, Bao Z, Jafri SM, Su X, Cao Z, Xiong G, Zhang L, Woldu S, Hutchinson R, Sagalowsky A, Lotan Y, Li X, Raman JD, Margulis V, Zhou L. The Significance of Preoperative Serum Sodium and Hemoglobin in Outcomes of Upper Tract Urothelial Carcinoma: Multi-Center Analysis Between China and the United States. Cancer Manag Res. 2020 Oct 8;12:9825-9836. doi: 10.2147/CMAR.S267969. eCollection 2020.PMID: 33116841
  • Howard JM, Margulis V, Woldu SL. Clinical outcomes of a cohort of patients with bulky, clinically node-positive bladder cancer undergoing radical cystectomy in the contemporary era. Can Urol Assoc J. 2020 Oct 27. doi: 10.5489/cuaj.6966. Online ahead of print.PMID: 33119506
  • Bagrodia A, Savelyeva A, Lafin JT, Speir RW, Chesnut GT, Frazier AL, Woldu SL, Margulis V, Murray MJ, Amatruda JF, Lotan Y. Impact of circulating microRNA test (miRNA-371a-3p) on appropriateness of treatment and cost outcomes in patients with Stage I non-seminomatous germ cell tumours. BJU Int. 2020 Oct 30. doi: 10.1111/bju.15288. Online ahead of print.PMID: 33124175
  • Howard JM, Woldu SL, Daneshmand S, Lotan Y. Enhanced Endoscopy with IMAGE1 S CHROMA Improves Detection of Nonmuscle Invasive Bladder Cancer During Transurethral Resection. J Endourol. 2020 Dec 4. doi: 10.1089/end.2020.0821. Online ahead of print.PMID: 33176470
  • Bhanvadia RR, Khouri RK Jr, Ashbrook C, Woldu SL, Margulis V, Raj GV, Bagrodia A. Safety, Efficacy, and Impact on Quality of Life of Palliative Robotic Cystectomy for Advanced Prostate Cancer Clin Genitourin Cancer. 2020 Nov 2:S1558-7673(20)30231-7. doi: 10.1016/j.clgc.2020.09.008. Online ahead of print. PMID: 33246846
  • Badia RR, Woldu S, Patel HD, Singla N, Srivastava A, Cheaib JG, Pierorazio PM, Bagrodia A. Clinical utility of the AJCC 8 th edition pT1 subclassification and impact on practice patterns in stage I seminoma. Clin Genitourin Cancer. 2020 Nov 2:S1558-7673(20)30231-7. doi: 10.1016/j.clgc.2020.09.008. Online ahead of print.PMID: 33246846
  • Woldu SL, Ng CK, Loo RK, Slezak JM, Jacobsen SJ, Tan WS, Kelly JD, Lough T, Darling D, van Kessel KEM, de Jong JJ, van Criekinge W, Shariat SF, Hiar A, Brown S, Boorjian SA, Barocas DA, Svatek RS, Lotan Y. Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria. J Urol. 2020 Dec 24:101097JU0000000000001550. doi: 10.1097/JU.0000000000001550. Online ahead of print.PMID: 33356483
  • Ames KS, Baky F, Blair S, Sanchez J, Franklin W, Barefoot A, Mears J, Magness P, Johnson B, Bakare T, Hudak S, Antonelli J, Hutchinson R, Lotan Y, Woldu SL. Simple Nephrectomy in a Tertiary Care Safety Net Hospital-Patient Characteristics, Causes, Cost, and Renal Function Implications. Urology. 2020 Dec 24:S0090-4295(20)31503-X. doi: 10.1016/j.urology.2020.12.013. Online ahead of print.PMID: 33359487
  • Margulis V, Friefeld Y, Pop LM, Manna S, Kapur P, Pedrosa I, Christie A, Mohamad O, Mannala S, Singla N, Wait M, Bagrodia A, Woldu SL, Gahan J, Brugarolas J, Timmerman R, Hannan R. Neoadjuvant SABR for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombus-Safety Lead-in Results of a Phase 2 Trial. Int J Radiat Oncol Biol Phys 2021 Feb 5;S0360-3016(21)00163-2. doi: 10.1016/j.ijrobp.2021.01.054. PMID: 33549705
  • Baky FJ, Bhanvadia RR, Badia RR, Woldu S, Bagrodia A. Encouraging Outcomes Allow Patient-Guided Treatment Strategies for Stage I Pure Testicular Teratoma. Ann Surg Oncol. 2021 Mar 22. doi: 10.1245/s10434-021-09700-w. PMID: 33754225
  • Woldu SL, Souter L, Boorjian SA, Barocas DA, Lotan Y. Urinary-Based Tumor Markers Enhance Microhematuria Risk Stratification According to Baseline Bladder Cancer Prevalence. Urol Oncol. 2021 Apr 12;S1078-1439(21)00132-0. doi: 10.1016/j.urolonc.2021.03.022. PMID: 33858747
  • Lafin JT, Kenigsberg AP, Meng X, Abe D, Savelyeva A, Singla N, Woldu SL, Lotan Y, Mauck RJ, Lewis CM, Margulis V, Wong D, Jia L, Kapur P, Xu L, Speir RW, Chesnut GT, Frazier AL, Strand DW, Coleman N, Murray MJ, Amatruda JF, Bagrodia A. Serum Small RNA Sequencing and miR-375 Assay Do Not Identify the Presence of Pure Teratoma at Postchemotherapy Retroperitoneal Lymph Node Dissection. Eur Urol Open Sci. 2021 Apr;26:83-87. doi: 10.1016/j.euros.2021.02.003. Epub 2021 Mar 5. PMID: 33997822
  • Howard JM, Nandy K, Woldu SL, Margulis V. Demographic Factors Associated With Non-Guideline-Based Treatment of Kidney Cancer in the United States. JAMA Netw Open. 2021 Jun 1;4(6):e2112813. doi: 10.1001/jamanetworkopen.2021.12813. PMID: 34106265
  • Miranda AF, Howard JM, McLaughlin M, Meng X, Clinton T, Şanli Ö, Garant A, Bagrodia A, Margulis V, Lotan Y, Hannan R, Desai N, Woldu SL. Metastasis-directed radiation therapy after radical cystectomy for bladder cancer. Urol Oncol. 2021 Jun 29:S1078-1439(21)00212-X. doi: 10.1016/j.urolonc.2021.05.005. Online ahead of print. PMID: 34215505
  • Ghandour RA, Freifeld Y, Cheaib J, Singla N, Meng X, Kenigsberg A, Bagrodia A, Woldu S, Hoffman-Censits J, Enikeev D, Rapoport L, Petros FG, Raman JD, Pierorazio PM, Matin SF, Margulis V. Predictive model for systemic recurrence following cisplatin-based neoadjuvant chemotherapy and radical nephroureterectomy for high risk upper tract urothelial carcinoma. Urol Oncol. 2021 Jul 28:S1078-1439(21)00259-3. doi: 10.1016/j.urolonc.2021.05.037. Online ahead of print. PMID: 34330655

Clinical Focus

  • Urologic Cancer, Masses, and Tumors
  • Bladder Cancer
  • Kidney Cancer
  • Prostate Cancer
  • Testicular Cancer
  • General Urology

See More

Results: 1 Locations

Urology Clinic

at West Campus Building 3 2001 Inwood Road, 4th Floor
Dallas, Texas 75390 214-645-8765 Directions to Urology Clinic Parking Info for Urology Clinic

Appointment New Patient Appointment Accepting Virtual Visits or 214-645-8765